Iovance Biotherapeutics, Inc. (IOVA)
8.635
+0.36
(+4.29%)
USD |
NASDAQ |
Sep 02, 16:00
8.66
+0.02
(+0.29%)
After-Hours: 20:00
Iovance Biotherapeutics Cash from Operations (Annual) : -302.41M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -302.41M |
| December 31, 2024 | -352.98M |
| December 31, 2023 | -361.82M |
| December 31, 2022 | -292.76M |
| December 31, 2021 | -227.94M |
| December 31, 2020 | -205.13M |
| December 31, 2019 | -158.89M |
| December 31, 2018 | -101.25M |
| December 31, 2017 | -78.71M |
| Date | Value |
|---|---|
| December 31, 2016 | -32.67M |
| December 31, 2015 | -18.38M |
| December 31, 2014 | -8.633M |
| December 31, 2013 | -3.662M |
| December 31, 2012 | -2.242M |
| December 31, 2011 | -6.189M |
| December 31, 2010 | -0.6208M |
| December 31, 2009 | -0.0144M |
| December 31, 2008 | -0.0573M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Amgen, Inc. | 9.958B |
| Halozyme Therapeutics, Inc. | 651.56M |
| Neurocrine Biosciences, Inc. | 782.70M |
| AVITA Medical, Inc. | -31.20M |
| Editas Medicine, Inc. | -165.24M |